Literature DB >> 22951242

Discussion: a fresh look at monoamine oxidase inhibitors for depression.

Lawrence J Cohen, David A Sclar, Larry Culpepper, David A Flockhart, Robert M A Hirschfeld, Michael E Thase, Chad M VanDenBerg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22951242     DOI： 10.4088/JCP.11096su1c.07

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN： 0160-6689            Impact factor:   4.384


× No keyword cloud information.
  4 in total

1.  Role of Macrophage Dopamine Receptors in Mediating Cytokine Production: Implications for Neuroinflammation in the Context of HIV-Associated Neurocognitive Disorders.

Authors:  R A Nolan; R Muir; K Runner; E K Haddad; P J Gaskill
Journal:  J Neuroimmune Pharmacol       Date:  2018-12-05       Impact factor: 4.147

2.  Reducing the Burden of Difficult-to-Treat Major Depressive Disorder: Revisiting Monoamine Oxidase Inhibitor Therapy.

Authors:  Larry Culpepper
Journal:  Prim Care Companion CNS Disord       Date:  2013-10-31

3.  Higher patient satisfaction with antidepressants correlates with earlier drug release dates across online user-generated medical databases.

Authors:  Scott Siskind; Roland C Aydin; Punit Matta; Christian J Cyron
Journal:  Pharmacol Res Perspect       Date:  2017-10

4.  Early Improvement with Vortioxetine Predicts Response and Remission: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan.

Authors:  Takeshi Inoue; Shinji Fujimoto; Tatsuro Marumoto; Tadayuki Kitagawa; Kazuyuki Ishida; Tadashi Nakajima; Yoshiya Moriguchi; Keita Fujikawa; Koichiro Watanabe
Journal:  Neuropsychiatr Dis Treat       Date:  2021-12-18       Impact factor: 2.570
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.